Human Herpesvirus Replication and Abnormal CD8+ T Cell Activation and Low CD4+ T Cell Counts in Antiretroviral-Suppressed HIV-Infected Patients

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Jacobson, Mark A ^a   Ditmer, Dirk P ^b   Sinclair, Elizabeth ^a   Martin, Jeffrey N ^a   Deeks, Steven G ^a   Hunt, Peter ^a   Mocarski, Edward S ^c   Shiboski, Caroline ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PRIMER DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SIMPLEXVIRUS; VIRUS REPLICATION;

EID: 67650270381     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005277     Document Type: Article

References (29)

1. Kelly CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, et al.(2009) Incomplete peripheral CD4+ cell count restoration among long-term antiretroviral treated HIV infected patients. Clin Infect Dis 48: 787-794.
2. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al.(2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-43.
3. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V, (2002) Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr 31: 472-727.
4. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al.(1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-70.
5. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, et al.(1997) Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 16: 83-92.
6. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al.(2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
7. Jiang W, Lederman MM, Hunt PW, Sieg SF, Haley K, et al.(2009) Plasma levels of bacterial DNA correlate with immune activation and predict the magnitude of immune restoration in antiretroviral-treated HIV infection. J Infect Dis Mar 5[Epub ahead of print].
8. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, et al.(2006) Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 20: 2275-83.
9. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, et al.(2004) Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2: E20.
10. Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, et al.(2008) Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 198: 23-30.
11. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, et al.(2006) High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J Clin Microbiol 44: 2409-15.
12. Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, et al.(2002) The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73: 968-73.
13. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA, (1997) Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 64: 108-13.
14. van Baarle D, Kostense S, Hovenkamp E, Ogg G, Nanlohy N, et al.(2002) Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. AIDS 16: 2001-2011.
15. Potena L, Holweg CT, Vana ML, Bashyam L, Rajamani J, et al.(2007) Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol 45: 1804-10.
16. Hilscher C, Vahrson W, Dittmer DP, (2005) Faster quantitative real-time PCR protocols may lose sensitivity and show increased variability. Nucleic Acids Res 33: e182.
17. Jebbink J, Bai X, Rogers BB, Dawson DB, Scheuermann RH, et al.(2003) Development of real-time PCR assays for the quantitative detection of Epstein-Barr virus and cytomegalovirus, comparison of TaqMan probes, and molecular beacons. J Mol Diagn 5: 15-20.
18. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al.(2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-71.
19. Brenchley JM, Price DA, Douek DC, (2006) HIV disease: fallout from a mucosal catastrophe? Nat Immunol 7: 235-9.
20. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, et al.(2003) Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77: 11212-9.
21. Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, et al.(2008) HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res 6: 261-6.
22. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, et al.(2007) RT suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3: e46.
23. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al.(2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879-84.
24. Hatano H, Delwart E, Norris P, Hoh R, Busch M, et al.(2009) Longitudinal Measurements of Ultra-sensitive Plasma HIV RNA and Quantitative Antibody Levels in HIV-1-infected Individuals Who Naturally Maintain Viral Loads below the Limit of Conventional Detection 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada. Abstract #347.
25. Malhotra U, Huntsberry C, Holte S, Lee J, Corey L, McElrath MJ, (2006) CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression. Clin Immunol 119: 95-102.
26. Jiao Y, Fu J, Xing S, Fu B, Zhang Z, et al.(2008) The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8(+) T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology {Epub ahead of print].
27. Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM, (2008) FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol 83: 254-62.
28. Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, et al.(2007) Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 21: 1525-34.
29. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, et al.(2005) Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 174: 4407-14.